QLS1410 for People With Uncontrolled High Blood Pressure
Tests QLS1410 tablets against placebo in adults with uncontrolled hypertension.
Plain-language title generated from the registry record
Registry title: QLS1410 in Participants With Uncontrolled Hypertension
Key facts
- Where
- Jinan, ChinaSee the site
- Phase
- Phase 2
Where in China
- Qilu Hospital of Shandong UniversityJinan, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Qilu Pharmaceutical Co., Ltd.
- Trial code
- NCT07489612
- Record updated
- 22 May 2026
- Original description
The goal of this clinical trial is to measure the efficacy and safety of QLS1410 in participants with uncontrolled hypertension (uHTN) or treatment-resistant hypertension (rHTN). The main objective is to compare the difference in systolic blood pressure（SBP) change from baseline at Week 12 of treatment between participants receiving QLS1410 tablets and participants receiving placebo tablets.Read full original descriptionShow less
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of QLS1410 in Participants With Uncontrolled Hypertension
The goal of this clinical trial is to measure the efficacy and safety of QLS1410 in participants with uncontrolled hypertension (uHTN) or treatment-resistant hypertension (rHTN). The main objective is to compare the difference in systolic blood pressure（SBP) change from baseline at Week 12 of treatment between participants receiving QLS1410 tablets and participants receiving placebo tablets.
Inclusion: Male or female participants must be ≥ 18 years old; Mean seated SBP ≥ 140 mmHg at Screening and at Baseline; Fulfil at least 1 of the following 2 criteria:; Uncontrolled Hypertension (uHTN) subpopulation: have a stable regimen (≥ 4 weeks) of 2 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator; Resistant Hypertension (rHTN) subpopulation: have a stable regimen (≥ 4 weeks) of ≥ 3 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator.
Exclusion: Has the following known secondary causes of hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation; NYHA functional heart failure class IV at Screening; Serum potassium (K+) level <3.5 and ≥ 5.0 mmol/L; Mean seated systolic blood pressure (SBP)≥ 180 mmHg; Mean seated diastolic blood pressure (DBP)≥ 110 mmHg; Estimated glomerular filtration rate < 45 mL/min/1.73m2.